STOCK TITAN
  1. Home
  2. News
  3. GERN

Geron Corp - GERN STOCK NEWS

Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.

Geron Corporation (GERN) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class therapies for cancer. The company's cornerstone product candidate is Imetelstat, a novel telomerase inhibitor currently in clinical development. Telomerase is an enzyme that allows cancer cells to maintain telomere length, essential for limitless cellular replication.

Imetelstat is a potent, specific inhibitor of telomerase and holds promise for treating various hematologic myeloid malignancies. Based on clinical data obtained in late 2012, Geron is exploring the potential of Imetelstat to treat conditions such as myelofibrosis (MF), myelodysplastic syndromes (MDS), and acute myelogenous leukemia (AML).

Geron earns revenue through a mix of collaboration agreements, milestones, royalties, and licensing arrangements. The company is the exclusive developer of Imetelstat and possesses various rights to the drug. Operating as a single segment focused on oncology, Geron is committed to advancing its research to bring effective cancer treatments to market.

Stay updated with the latest news and developments from Geron Corporation to learn more about their groundbreaking research and progress in cancer treatment.

News

Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS

Rhea-AI Summary
Geron Corporation (Nasdaq: GERN) announced data from its IMerge Phase 3 clinical trial evaluating telomerase inhibitor imetelstat in lower risk myelodysplastic syndromes patients, presenting significant clinical benefits and safety profile at the ASH Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
acquisition clinical trial
-
News

Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

Rhea-AI Summary
Geron Corporation (GERN) achieves 50% enrollment in Phase 3 IMpactMF clinical trial for imetelstat in relapsed/refractory myelofibrosis patients. Interim analysis expected in H1 2025, final analysis in H1 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
clinical trial
-
News

Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

Rhea-AI Summary
Geron Corporation (GERN) announced the publication of results from the IMerge Phase 3 trial investigating imetelstat versus placebo in patients with lower risk myelodysplastic syndromes (MDS) relapsed/refractory or ineligible for erythropoiesis stimulating agents (ESAs). The publication in The Lancet validates the study's importance within the field and reaches hematologists and other providers globally with potentially practice-changing results. Imetelstat is currently under regulatory review by the FDA and EMA for approval in transfusion-dependent anemia in patients with lower risk MDS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.53%
Tags
acquisition clinical trial
News

Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors

Rhea-AI Summary
Geron Corporation (GERN) appoints Dr. Gaurav Aggarwal, a prominent investor in the life sciences sector, to its Board of Directors. Dr. Aggarwal brings extensive strategic leadership and a demonstrated track record in corporate strategy and capital formation. His appointment is expected to add tremendous value as the company looks forward to a potential commercial launch in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Geron Corporation (Nasdaq: GERN) Grants Stock Options to Newly Hired Employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.35%
Tags
none
-
News

Geron to Participate at Upcoming Investor Conferences in November

Rhea-AI Summary
Geron Corporation (GERN) to Present at Investor Conferences, Webcasts Available - GERN Stock News
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.14%
Tags
conferences
News

Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS

Rhea-AI Summary
Geron Corporation announces publication of abstracts from the IMerge Phase 3 clinical trial of imetelstat in patients with lower risk myelodysplastic syndromes (MDS). The abstracts highlight that imetelstat achieved transfusion independence (TI) in patients across different risk groups and mutational profiles. Nearly 20% of imetelstat-treated patients achieved sustained TI for over 1 year with a median duration of TI of more than 2 years and a median hemoglobin increase of more than 5 g/dL. Imetelstat demonstrated efficacy in patients reclassified as higher risk using molecular international prognostic scoring system (IPSS-M).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.77%
Tags
acquisition clinical trial
-
News

Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results

Rhea-AI Summary
Geron Corporation reported business highlights and financial results for Q3 2023. Imetelstat, a telomerase inhibitor, is under regulatory review by the FDA and EMA for the treatment of transfusion-dependent anemia in adult patients with lower risk MDS. The FDA assigned a PDUFA action date of June 16, 2024. Planning is ongoing for a potential commercial launch in the U.S. in mid-2024. Geron has approximately $382 million on the balance sheet as of the end of the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.77%
Tags
earnings
-
News

Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023

Rhea-AI Summary
Geron Corporation will release its Q3 2023 financial results and business highlights on November 2, 2023. A conference call will be held at 9:00 a.m. ET the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
earnings
News

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Geron Corporation grants stock options to newly hired employees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
none

FAQ

What is the current stock price of Geron (GERN)?

The current stock price of Geron (GERN) is $4.07 as of November 22, 2024.

What is the market cap of Geron (GERN)?

The market cap of Geron (GERN) is approximately 2.5B.

What is the primary focus of Geron Corporation?

Geron Corporation is focused on developing first-in-class cancer therapies, particularly a telomerase inhibitor named Imetelstat.

What is Imetelstat?

Imetelstat is a novel, first-in-class telomerase inhibitor developed by Geron Corporation for treating various hematologic myeloid malignancies.

Which conditions is Imetelstat being developed to treat?

Imetelstat is being developed to treat myelofibrosis (MF), myelodysplastic syndromes (MDS), and acute myelogenous leukemia (AML).

How does Imetelstat work?

Imetelstat works by inhibiting telomerase, an enzyme that enables cancer cells to maintain telomere length and replicate indefinitely.

What revenue streams does Geron Corporation rely on?

Geron earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements.

Is Geron Corporation a diversified company?

No, Geron operates as a single segment focused on the development of therapeutic products for oncology.

What is the significance of telomerase in cancer treatment?

Telomerase allows cancer cells to maintain telomere length, which is crucial for their endless replication. Inhibiting telomerase can potentially limit cancer growth.

Has Geron Corporation achieved any significant milestones?

Yes, Geron has obtained promising clinical data for Imetelstat and continues to develop it for various cancer treatments.

Where can I find the latest news about Geron Corporation?

You can find the latest news and developments about Geron Corporation on their official website and dedicated stock market websites like StockTitan.

What makes Imetelstat unique among cancer therapies?

Imetelstat is unique because it is a first-in-class telomerase inhibitor, targeting a critical enzyme that allows cancer cells to replicate indefinitely.

Stock GERN logo
Geron Corp

Nasdaq:GERN

GERN Rankings

#1845 Ranked by Market Cap
N/A Ranked by Dividends

GERN Stock Data

2.48B
603.98M
0.09%
85.33%
12.64%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
FOSTER CITY